PRCT Relative Valuation
PRCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRCT is overvalued; if below, it's undervalued.
Historical Valuation
Procept Biorobotics Corp (PRCT) is now in the Fair zone, suggesting that its current forward PS ratio of 9.30 is considered Fairly compared with the five-year average of -27.11. The fair price of Procept Biorobotics Corp (PRCT) is between 42.94 to 117.90 according to relative valuation methord.
Relative Value
Fair Zone
42.94-117.90
Current Price：57.45
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
8.23
P/B
Median3y
10.20
Median5y
9.08
-2.75
FCF Yield
Median3y
-4.63
Median5y
-4.56
Competitors Valuation Multiple
The average P/S ratio for PRCT's competitors is 3.13, providing a benchmark for relative valuation. Procept Biorobotics Corp Corp (PRCT) exhibits a P/S ratio of 9.30, which is 197.56% above the industry average. Given its robust revenue growth of 55.28%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Procept Biorobotics Corp (PRCT) currently overvalued or undervalued?
What is Procept Biorobotics Corp (PRCT) fair value?
How does PRCT's valuation metrics compare to the industry average?
What is the current P/B ratio for Procept Biorobotics Corp (PRCT) as of Jul 08 2025?
What is the current FCF Yield for Procept Biorobotics Corp (PRCT) as of Jul 08 2025?
What is the current Forward P/E ratio for Procept Biorobotics Corp (PRCT) as of Jul 08 2025?